UBS analyst John Sourbeer downgraded Maravai Lifesciences to Neutral from Buy with a price target of $16, down from $20. Sourbeer sees a lack of near-term catalysts with potential downside to the initial 2023 color provided in Q3, the analyst tells investors in a research note. The analyst awaits clarity regarding the long-term revenue growth trajectory of the NAP business and an update on new strategic initiatives following the CEO transition in June 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRVI:
- Maravai Lifesciences initiated with a Buy at Deutsche Bank
- Maravai Lifesciences initiated with an Outperform at RBC Capital
- Maravai LifeSciences Announces Updated CEO Leadership Transition Plans
- Maravai Lifesciences announces plans for William Martin to become CEO in 2023
- Maravai LifeSciences Named to the 2022 Deloitte Technology Fast 500™ List of Fastest-Growing Companies in North America